Repression of the *Arf* tumor suppressor by E2F3 is required for normal cell cycle kinetics

Aaron Aslanian,¹ Phillip J. Iaquinta,¹ Raluca Verona,² and Jacqueline A. Lees³

Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Tumor development is dependent upon the inactivation of two key tumor-suppressor networks, p16^{Ink4a}-cyclinD/CDK4-pRB-E2F and p19^{Arf}-MDM2-p53, that regulate cellular proliferation and the tumor surveillance response. These networks are known to intersect with one another, but the mechanisms are poorly understood. Here, we show that E2F directly participates in the transcriptional control of *Arf* in both normal and transformed cells. This occurs in a manner that is significantly different from the regulation of classic E2F-responsive targets. In wild-type mouse embryonic fibroblasts (MEFs), the *Arf* promoter is occupied by E2F3 and not other E2F family members. In quiescent cells, this role is largely fulfilled by E2F3b, an E2F3 isoform whose function was previously undetermined. *E2f3* loss is sufficient to derepress *Arf*, triggering activation of p53 and expression of p21^{Cip1}. Thus, E2F3 is a key repressor of the p19^{Arf}-p53 pathway in normal cells. Consistent with this notion, *Arf* mutation suppresses the activation of p53 and p21^{Cip1} in *E2f3*-deficient MEFs. *Arf* loss also rescues the known cell cycle re-entry defect of *E2f3*^{-/-} cells, and this correlates with restoration of appropriate activation of classic E2F-responsive genes. Our data also demonstrate a direct role for E2F in the oncogenic activation of *Arf*. Specifically, we observe recruitment of the endogenous activating E2Fs, E2F1, and E2F3a, to the *Arf* promoter. Thus, distinct E2F complexes directly contribute to the normal repression and oncogenic activation of *Arf*. We propose that monitoring of E2F levels and/or activity is a key component of *Arf*'s ability to respond to inappropriate, but not normal cellular proliferation.

[**Keywords:** Tumor surveillance; p19^{Arf}-p53; oncogenic activation; proliferation; E2F3]

Received February 20, 2004; revised version accepted April 20, 2004.

The development of mammalian tumors is dependent upon the disruption of two key biological activities, the control of cellular proliferation and the apoptotic response (Hanahan and Weinberg 2000). Remarkably, the *Ink4a/Arf* locus encodes two distinct tumor-suppressor proteins, p16^{Ink4a} and p19^{Arf} (p14^{Arf} in humans), that influence one or both of these processes (Chin et al. 1998; Sherr 2001). p16^{Ink4a} is a core component of the cell cycle control machinery (Sherr and Roberts 1999). It controls the activity of the G₁ kinase, cyclinD · CDK4/6, and consequently, the phosphorylation status of the pocket protein family. This family includes the retinoblastoma protein (pRB) tumor suppressor and its relatives, p107 and p130. In the unphosphorylated state, the pocket proteins bind to the E2F family of transcription factors and prevent the expression of genes that are essential for entry into, and passage through the cell cycle (Trimarchi and Lees 2002). This inhibition occurs through two dis-

tinct mechanisms. pRB binds to the activating E2Fs, E2F1, E2F2, and E2F3a, and blocks their transcriptional activity. At the same time, the repressive E2Fs, E2F4, and E2F5 recruit p107 or p130 and their associated histone deacetylases to E2F-responsive promoters. Under these conditions, the cell is blocked in G₀/G₁. Mitogenic signaling activates cell cycle re-entry by allowing cyclinD · CDK4/6 to overcome the repression by p16^{Ink4a}. The consequent phosphorylation of the pocket proteins causes them to dissociate from E2F, enabling activation of E2F-responsive genes. In normal cells, the p16^{Ink4a}-cyclinD · CDK4/6-pRB-E2F pathway responds to both positive and negative growth regulatory signals to determine whether or not a cell will divide (Sherr and Roberts 1999). This pathway is disrupted in most, if not all, mammalian tumors through loss of p16^{Ink4a}, up-regulation of cyclinD · CDK4/6 or loss of pRB (Sherr 1996). The resulting deregulated proliferation is due, at least in part, to the inappropriate activation of E2F (Pan et al. 1998; Tsai et al. 1998; Yamasaki et al. 1998; McCaffrey et al. 1999; Ziebold et al. 2001, 2003).

The second product of the *Ink4a/Arf* locus, p19^{Arf}, is a key component of the p53 tumor-surveillance network (Sherr 2001). p19^{Arf} exists at low or undetectable levels

¹These authors contributed equally to this work.

²Present address: University of Pennsylvania School of Medicine, Philadelphia, PA 19014, USA

³Corresponding author.

E-MAIL jalees@mit.edu; FAX (617) 253-9863.

Article published online ahead of print. Article and publication date are at <http://www.genesdev.org/cgi/doi/10.1101/gad.1196704>.

in most normal cell and tissue types (Zindy et al. 2003). However, its expression is specifically activated by abnormal proliferative signals. These include the continued in vitro culturing of mouse embryonic fibroblasts (MEFs; Kamijo et al. 1997) and the inappropriate expression of proliferative oncogenes including activated ras, c-myc, E2F, E1A, and v-Abl (Serrano et al. 1997; de Stanchina et al. 1998; Palmero et al. 1998; Radfar et al. 1998; Zindy et al. 1998; Dimri et al. 2000). Once it is expressed, p19^{Arf} inhibits the p53 ubiquitin ligase, mdm2, allowing activation of the p53 tumor suppressor (Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998; Honda and Yasuda 1999; Weber et al. 1999; Llanos et al. 2001). Depending on the cellular context, p53 triggers either cell cycle arrest (via induction of the cdk inhibitor, p21^{Cip1}) or apoptosis (through activation of various apoptosis inducers). In either case, this counteracts the effect of the abnormal proliferative signals. Essentially, p19^{Arf} acts as a defense to oncogenic signals. The recent analysis of a mouse strain that expresses GFP in place of p19^{Arf} confirms that *Arf* is induced by the oncogenic signals present in incipient tumors (Zindy et al. 2003). This explains why inactivation of the p19^{Arf}-p53 network is essential for the survival and proliferation of tumor cells in vivo (Sherr 2001).

The ability of *Arf* to specifically respond to inappropriate, but not normal proliferative signals must require a careful balance of transcriptional signals. Understanding how this is achieved remains a major challenge. Numerous studies have implicated E2F in this process (Phillips and Vousden 2001). The *Arf* promoter contains consensus E2F-binding sites and the overexpression of E2F1 is sufficient to trigger its transcriptional activation (DeGregori et al. 1997; Bates et al. 1998). However, it is unclear whether this regulation is direct because the identified E2F sites are not required for E2F-dependent activation (Parisi et al. 2002; Berkovich et al. 2003). There is also considerable debate as to which E2F family members might activate *Arf* (Trimarchi and Lees 2002). Some groups conclude that this is an E2F1-specific activity, whereas others propose that this is a shared property of the activating E2Fs. Certainly, E2F1 is not required for *Arf* induction in numerous settings (Palmero et al. 2002; Baudino et al. 2003) and p19^{Arf} itself is dispensable for E2F-dependent apoptosis (Russell et al. 2002; Tolbert et al. 2002; Tsai et al. 2002). These findings could reflect redundancy; perhaps multiple E2Fs can activate a large panel of apoptotic inducers that includes p19^{Arf}. Alternatively, E2F may not contribute to *Arf* activation in vivo. Others have suggested that *Arf* is regulated by repressive E2F · pocket protein complexes (Rowland et al. 2002). However, unlike classic E2F-responsive genes, *Arf* is not appreciably induced during cell cycle entry. Thus, if *Arf* is a genuine E2F target, it must be regulated in a distinct manner from classic E2F-responsive genes. In this study, we use *E2f3*-deficient MEFs to probe the role of E2F in *Arf* regulation. This analysis shows that a single member of the E2F family, *E2f3*, is required to maintain the transcriptional repression of *Arf* under normal proliferative conditions.

Results

E2f3 loss causes induction of p19^{Arf} and activation of p53 in primary cells

Two E2F family members, E2F3a and E2F3b, are encoded by a single locus through the use of different promoters and 5'-coding exons (Leone et al. 2000). These proteins share domains required for DNA binding, heterodimerization, and pocket protein binding, but have distinct N termini comprising either 122 (E2F3a) or 6 (E2F3b) amino acids. We have previously generated an *E2f3* mutant mouse strain that inactivates both of these proteins. For simplicity, we refer to these mice as *E2f3*^{-/-} or E2F3-deficient. MEFs derived from *E2f3*^{-/-} animals typically have a reduced rate of proliferation (Humbert et al. 2000). They also display a major defect in mitogen-induced cell cycle re-entry and a corresponding impairment in the activation of all known E2F-responsive genes examined (Humbert et al. 2000; Fig. 1A,B). Given these observations, we hypothesized that p19^{Arf} expression might be altered in E2F3-deficient MEFs if it is a bona fide E2F-target gene. To test this notion, we compared the levels of p19^{Arf} in early passage wild-type versus *E2f3*^{-/-} MEFs

Figure 1. *E2f3*^{-/-} MEFs have increased levels of p19^{Arf}, leading to activation of p53. (A) Wild-type MEFs (solid line) and *E2f3*^{-/-} MEFs (dotted line) were synchronized by serum starvation and cell cycle re-entry was monitored by [³H]thymidine incorporation. (B,C) Total protein extracts were prepared at the indicated times after stimulation with 10% serum and subjected to Western blotting for cyclin A, p107, p19^{Arf}, p16^{Ink4A}, or p21^{Cip1} (B,C), or electrophoretic mobility shift assay for active p53 (C).

during cell cycle re-entry (Fig. 1). Consistent with previous studies (Sherr and DePinho 2000), p19^{Arf} was barely detectable in the wild-type cells, and its expression did not vary significantly during the cell cycle (Fig. 1B). Strikingly, whereas the expression of the classic E2F-responsive targets, cyclin A and p107, was lower in the *E2f3*^{-/-} MEFs than the wild-type controls, that of p19^{Arf} was greatly increased (Fig. 1B). Thus, E2F3 loss affects p19^{Arf} expression, but in an entirely distinct manner from other E2F-responsive genes.

The predominant function of p19^{Arf} is to activate p53 by inhibiting its negative regulator, the ubiquitin ligase mdm2. We therefore used electrophoretic mobility shift assays (EMSA) to determine whether the induction of p19^{Arf} in the *E2f3*^{-/-} MEFs affected p53 activity (Figs. 1C, 2B). In wild-type MEFs, p53 DNA-binding activity remained low throughout the cell cycle. p53 activity was elevated in E2F3-deficient MEFs, especially during quiescence. The p53 protein also showed characteristic hallmarks of activation; there was an increase in the levels of p53 that was phosphorylated on Ser 15 and a subtle increase in the total p53 protein levels (data not shown). Thus, deregulation of p19^{Arf} in *E2f3*^{-/-} MEFs is accompanied by the activation of p53. A known downstream target of p53, the cdk inhibitor p21^{Cip1}, was also expressed at higher levels in the E2F3-deficient MEFs (Fig. 1C), as was p16^{Ink4a}, the other protein expressed from the *Ink4a/Arf* locus (Fig. 1B). It seemed likely that the elevated levels of p19^{Arf}, p53, and p21^{Cip1} might contribute to the defective cell cycle entry in the E2F3-deficient MEFs.

The up-regulation of p19^{Arf} accounts for the cell cycle re-entry defect of the E2f3^{-/-} MEFs

To address the biological consequences of p19^{Arf} up-regulation, we intercrossed *E2f3* and *Arf* mutant mice to generate *E2f3*^{-/-};*Arf*^{-/-} double-mutant (DKO) MEFs. We then examined the ability of these cells to re-enter the cell cycle relative to wild-type, *E2f3*^{-/-}, and *Arf*^{-/-} controls (Fig. 2A). Consistent with previous reports (Kamijo et al. 1997), the *Arf*^{-/-} MEFs initiated DNA synthesis more rapidly than the wild-type counterparts. Significantly, the cell cycle kinetics of the *E2f3*^{-/-};*Arf*^{-/-} DKO MEFs were indistinguishable from those of the *Arf*^{-/-} MEFs. Consistent with this rescue, *Arf* mutation also suppressed the defective mitogen-induced activation of classic E2F-responsive targets, such as cyclin A and p107, which exists in the *E2f3*^{-/-} cells (Fig. 2B). Thus, p19^{Arf} loss is sufficient to over-ride the cell cycle re-entry defect of the *E2f3*^{-/-} MEFs. EMSA and Western blotting experiments showed that *Arf* mutation also suppressed the activation of p53 and the induction of p21^{Cip1} in the *E2f3*^{-/-} MEFs (Fig. 2B), confirming that these events are dependent upon the up-regulation of p19^{Arf}. Importantly, p53 mutation suppressed the cell cycle re-entry defect of the *E2f3*^{-/-} MEFs in an analogous manner to *Arf* mutation (Fig. 2C). This correlated with suppression of the p21^{Cip1} induction and restoration of appropriate E2F-responsive gene activation (data not

Figure 2. Elimination of p19^{Arf} rescues cell cycle re-entry and p53 activation defects of *E2f3*-deficient MEFs. (A) Wild-type MEFs (solid black line), *E2f3*^{-/-} MEFs (dotted black line), *Arf*^{-/-} MEFs (solid gray line), and *E2f3*^{-/-};*Arf*^{-/-} DKO MEFs (dotted gray line) were synchronized by serum starvation and cell cycle re-entry was monitored by [³H]thymidine incorporation. (B) Total protein extracts were prepared at the indicated times after serum stimulation and subjected to Western blotting for cyclin A, p107, and p21^{Cip1}, or electrophoretic mobility shift assay for active p53. (C) Wild-type MEFs (solid black line), *E2f3*^{-/-} MEFs (dotted black line), *p53*^{-/-} MEFs (solid gray line), and *E2f3*^{-/-};*p53*^{-/-} DKO MEFs (dashed gray line) were analyzed exactly as described in A.

shown). Taken together, our findings indicate that *E2f3* is required to inhibit *Arf* expression, and this plays an important role in regulating normal cell cycle re-entry by preventing inappropriate activation of p53.

E2F3 directly contributes to the transcriptional regulation of Arf in normal cells

Although numerous studies implicate E2F in *Arf* control, it has not been shown that any E2F family member is a direct transcriptional regulator of this gene. To address this question, we first asked whether E2F3 loss

affects *Arf* at the transcriptional level. Using quantitative RT-PCR, we examined the mRNA levels of both *Arf* and a well-characterized E2F-responsive gene, *p107*, in wild-type versus E2F3-deficient MEFs (Fig. 3A). As in our previous studies (Humbert et al. 2000), the mitogen-induced activation of the *p107* transcript was greatly impaired in the *E2f3*^{-/-} MEFs. In contrast, *Arf* mRNA levels were significantly higher in *E2f3*^{-/-} MEFs than the wild-type controls (Fig. 3A). This up-regulation was most striking in the G₀ time point (Fig. 3A), where we observed the greatest increase in the levels of the p19^{Arf} protein (Fig. 1B). Thus, E2F3 loss is acting, at least in part, through changes in the levels of *Arf* mRNA. To determine whether E2F3 is directly involved in *Arf* regulation, we used chromatin immunoprecipitation (ChIP) to examine binding of E2F family members to the *Arf* and *p107* promoters (Fig. 3B). In asynchronously growing wild-type MEFs, we detected no significant enrichment of any E2F at a control sequence lacking E2F sites, 1 kb upstream of the E2F1 promoter. In contrast, several E2F family members could be detected at the *p107* promoter

including E2F1, E2F2, E2F3, and E2F4 (Fig. 3B; data not shown). This is entirely consistent with the previous characterization of archetypal mammalian E2F-responsive genes (Takahashi et al. 2000). Remarkably, the spectrum of E2F proteins at the *Arf* promoter differed completely from this norm; we observed only a single E2F, E2F3 (Fig. 3B). This specificity was not restricted to murine cells, as E2F3 was also the sole E2F bound to the *p14^{Arf}* promoter in both primary (WI-38) and transformed (T98G, BJ-T) human cell lines (data not shown). In *E2f3*^{-/-} MEFs, there was no longer any enrichment of the *Arf* or *p107* promoter sequences by the anti-E2F3 antibodies, confirming their specificity (Fig. 3B). Strikingly, E2F3 deficiency caused a slight increase in the level of E2F1 associated with the *p107* promoter, but there was no evidence of E2F1, or any other E2F family member binding to the *Arf* promoter in these cells (Fig. 3B). Taken together, these data show that E2F3 is directly involved in the regulation of *Arf*, and that loss of E2F3, without apparent recruitment of E2F1, is sufficient to allow *Arf* activation. On the basis of these findings, we

Figure 3. E2F3 is a direct repressor of *Arf*. (A) Wild-type (solid lines) or *E2f3*^{-/-} (dotted lines) MEFs were synchronized by serum starvation, and RNA was extracted at the indicated times after stimulation. Quantitative real-time RT-PCR analysis of *p107* or *Arf* mRNA is shown. (B) ChIP analysis of asynchronous wild-type (WT) or *E2f3*^{-/-} MEFs. Sonicated, cross-linked chromatin was immunoprecipitated with the indicated antibodies, and the purified DNA was analyzed by PCR with primers specific for the *p107* or *Arf* promoters, or a control sequence lacking E2F sites (1 kb upstream of the *E2f1* promoter). Input, 0.5% of chromatin in IP reactions was analyzed by PCR. (C) Schematic of the E2F3a and E2F3b proteins, and the antibodies used in ChIP analysis. (Black box) DNA-binding domain; (light gray box) dimerization domain; (dark gray box) transactivation domain. (D) Cell lysates of asynchronous (AS) wild-type MEFs or wild-type MEFs incubated in 0.1% serum for 3 d (SS) were subjected to Western blotting for the two E2F3 isoforms. ChIP assays for the indicated E2F and pocket protein family members were performed on the serum-starved wild-type MEFs.

conclude that E2F3 represses *Arf* expression in normal cells.

It is well established that the E2F proteins can contribute to the repression of E2F-responsive genes through recruitment of the pocket proteins, pRB, p107, and p130, and their associated histone deacetylases (Trimarchi and Lees 2002). The E2F3 proteins have been reported to bind to pRB, but not p107 or p130, in vivo (Moberg et al. 1996; He et al. 2000; Leone et al. 2000). Given this finding, we used ChIP assays to determine whether one or more pocket proteins were recruited to the *Arf* promoter along with E2F3 (Fig. 3B). Consistent with previous studies, p130, but not pRB, was readily detected at the *p107* promoter. In contrast, none of the pocket proteins were detected at the *Arf* promoter (Fig. 3B,D; data not shown). It is entirely possible that pRB is present, but cannot be detected due to limitations in the assay, the antibodies or the structure of the pRB/E2F3 repressive complex. However, we consistently detect pRB at differentiation-associated promoters using the same ChIP conditions (T. Yuan and J.A. Lees, unpubl.). This raises the possibility that E2F3 mediates *Arf* repression in a pocket protein-independent manner.

The E2F3 locus encodes two proteins, E2F3a and E2F3b, which differ only in their N-terminal sequences (Leone et al. 2000; Fig. 3C). E2F3a has been linked to the transcriptional activation of E2F-responsive genes, but this does not rule out a role in repression. The transcriptional properties of E2F3b have not been established. To discern which species of E2F3 is responsible for regulation of *Arf*, we made use of two antibodies raised against the E2F3 proteins. The sc-879x antibody recognizes an epitope on the unique N terminus of E2F3a, and therefore, does not cross-react with E2F3b. In contrast, a C-terminal antibody (sc-878x) recognizes both E2F3a and E2F3b. For clarity, we will refer to these antibodies as E2F3a specific or anti-E2F3a+b. By detecting ectopically expressed E2F3a and E2F3b proteins, we have confirmed the specificity of these two reagents (data not shown). These experiments also showed that the E2F3a-specific antibody has a considerably lower activity in ChIP assays than anti-E2F3a+b (data not shown). Despite its low avidity, the E2F3a-specific antibody yielded a detectable ChIP signal at the *p107* promoter (Fig. 3B). Under the same conditions, we did not see any evidence of E2F3a binding to *Arf* (Fig. 3B); however, because of the poor avidity of the E2F3a-specific antibody, we cannot rule out that E2F3a contributes to the repression of *Arf*, yet falls beneath the detection limit of this reagent. To address this in an alternative way, we took advantage of the differential expression patterns of the two E2F3 species. E2F3a expression is cell cycle regulated, peaking during the G₁/S transition, whereas E2F3b expression is constant throughout the cell cycle. Consequently, E2F3b is the only E2F3 isoform expressed during quiescence (Fig. 3D). Therefore, we performed ChIP from MEFs that had been arrested in G₀/G₁ by serum deprivation (Fig. 3D). In this setting, the *p107* promoter was specifically occupied by E2F4 and p130, the key components of the archetypal repressive E2F/pocket protein complex. At the same

time, we still specifically detected E2F3 at the *Arf* promoter using the anti-E2F3a+b antibody. This analysis strongly implicates E2F3b in the repression of *Arf* in quiescent cells, yet does not exclude contribution of E2F3a, along with E2F3b, in asynchronous cells.

The activating E2Fs are directly involved in activation of Arf in response to oncogenic stress

It is well documented that *Arf* is a key regulator of the mammalian tumor-surveillance-response network. Through an as yet undetermined mechanism, the inappropriate expression of numerous oncogenes induces the expression of p19^{Arf}. The resulting p53 activation triggers either cell cycle arrest (via p21^{Cip1} induction) or apoptosis (through activation of pro-apoptotic genes), thereby circumventing the oncogenes' ability to drive inappropriate proliferation. Having established a direct role for E2F3 in repression of *Arf* in unstressed cells, we sought to determine what role E2F might play during the activation of *Arf* by oncogenic challenge.

E2F1 is a potent oncogene. Its over-expression activates both cellular proliferation and also the induction of p19^{Arf} and high levels of apoptosis (DeGregori et al. 1997; Bates et al. 1998). This latter response greatly impedes investigation of the underlying molecular mechanisms. To overcome this problem, we have used MEFs in which exons 2 and 3 of the *Ink4a/Arf* locus are deleted (*Ink4a/Arf*^{-/-} MEFs) and therefore p16^{Ink4a} and p19^{Arf} expression is disrupted (Serrano et al. 1996; Fig. 4A). This mutation does not affect the upstream regulatory region of *Arf*, which is ~13 kb upstream of the deletion, allowing us to examine E2F binding at the *Arf* promoter in the absence of apoptosis or other secondary events that might result from p19^{Arf} induction. We infected these *Ink4a/Arf*^{-/-} MEFs with either control or E2F1-expressing retroviruses and used ChIP to assess E2F binding to either the *Arf* or *p107* promoters (Fig. 4B). When *Ink4a/Arf*^{-/-} MEFs were infected with a control retrovirus, the spectrum of E2F complexes detected at the *Arf* and *p107* promoters was similar to that observed in wild-type, uninfected cells. Overexpression of E2F1 increased the level of E2F1 associated with the *p107* promoter, and caused a coordinate decrease in levels of bound E2F3 and p130 (Fig. 4B). This is consistent with the E2F1's known ability to promote cell cycle progression and activate expression of classic E2F-responsive genes (Trimarchi and Lees 2002). Strikingly, we also detected significant levels of E2F1 at the *Arf* promoter, showing that E2F1 can directly contribute to the transcriptional activation of *Arf* when it is inappropriately expressed (Fig. 4B).

We wished to determine whether the endogenous E2F1 participates in the induction of *Arf* by other oncogenes. To address this question, we examined the effect of overexpressing the adenoviral oncoprotein, E1A (Fig. 4B). This promotes proliferation and tumorigenesis by sequestering the pocket proteins and relieving the transcriptional inhibition of their associated E2Fs (Ben-Israel and Kleinberger 2002). In *Ink4a/Arf*^{-/-} MEFs expressing E1A, we observed a decrease in p130 binding to the *p107*

Aslanian et al.

Figure 4. The activating E2Fs bind to the *Arf* promoter during oncogenic challenge. (A) Schematic of the mouse *Ink4a/Arf* locus, indicating the exon structure, and the region deleted in the *Ink4a/Arf*^{-/-} MEFs (bracket). Shaded regions in the exons indicate regions coding for the p16^{Ink4a} (light gray) and p19^{Arf} (black) proteins. The small black boxes indicate two consensus E2F-binding sites in the *Arf* promoter, and the two small arrows indicate the location of the primers used in ChIP analysis. (B) *Ink4a/Arf*^{-/-} MEFs were infected with retrovirus overexpressing E2F1, E1A, or an empty virus (vector) and subjected to ChIP assays with the indicated antisera.

promoter, and an increase in E2F1 binding, as expected (Fig. 4B). Notably, we also detected E2F1 binding to the *Arf* promoter, showing that the endogenous E2F1 protein contributes to the activation of *Arf* arising from E1A expression. In addition, we detected a weak signal with the E2F3a-specific antibody, indicating that E2F3a was cooperating with E2F1 in the transcriptional regulation of *Arf*. Given these findings, we conclude that the endogenous activating E2Fs play a direct role in the oncogene-induced activation of *Arf* and the tumor-surveillance network.

Discussion

Taken together, our data show that the E2F proteins play a direct role in the transcriptional regulation of *Arf*. This firmly establishes *Arf* as a bona fide E2F-responsive gene. However, the nature of this regulation diverges consid-

erably from that of archetypal E2F-responsive targets; for example, genes encoding key components of the cell cycle control and DNA replication machinery (Fig. 5). These classic E2F-responsive genes are expressed in a cell cycle-dependent manner that is orchestrated by the specific binding of the repressive E2F/pocket protein complexes (predominantly E2F4/p130) during G₀/G₁ or the activating E2Fs (E2F1, E2F2, and E2F3a) during late G₁ and G₁/S phase. In contrast, our data show that *Arf* is regulated by a more restricted subset of E2F complexes, whose activity is somehow determined by the stress status, rather than the cell cycle staging of the cell.

In normal cells, *Arf* is constitutively repressed, and our data show that this correlates with the promoter binding of E2F3, and not other E2F family members. Because the E2F3a-specific antibody works poorly in ChIP assay, our inability to detect a signal with this reagent does not exclude the possibility that E2F3a contributes to *Arf* regulation. In contrast, the presence of a robust anti-E2F3a+b ChIP signal in quiescent cells that express E2F3b and not E2F3a, clearly shows that E2F3b is involved. At least in MEFs, the absence of E2F3 is sufficient to trigger the expression of *Arf*, without obligatory recruitment of the activating E2Fs. Thus, E2F3b (possibly in parallel with E2F3a) is required for the constitutive repression of *Arf* in normal cells. On the basis of its high expression in G₀/G₁ cells, E2F3b had been proposed to function as a transcriptional repressor (Leone et al. 2000). Our data provide the first direct evidence for this hypothesis.

Remarkably, our analysis of the double-mutant MEFs shows that *Arf* loss completely suppresses the cell cycle entry defect of the *E2f3*^{-/-} MEFs. This correlates with the loss of activation of the p53 pathway and also restoration of the normal cell cycle-dependent activation of classic E2F-responsive genes. This genetic rescue experiment is entirely consistent with the notion that E2F3 is acting to repress *Arf*, and therefore p53, in a linear pathway. How-

Figure 5. *Arf* is regulated by E2F in a distinct manner from classic E2F-responsive genes.

ever, it is also possible that the loss of *Arf* (or *p53*) confers a proliferative advantage on the cells that outweighs or overrides the proliferative disadvantage that results from *E2f3* loss. In this scenario, *Arf* and *E2f3* could be acting in parallel pathways or, alternatively, *E2f3* could exert its effects through both *Arf/p53*-dependent and *Arf/p53*-independent mechanisms. We currently favor the second alternative. Taken together, the presence of E2F3 at the *Arf* promoter and the derepression of *Arf* in *E2f3*^{-/-} MEFs strongly support the existence of an *Arf*-dependent mechanism. However, additional experiments indicate that the p19^{Arf}-p53 pathway does not fully account for the phenotypic consequences of E2F3 loss. First, whereas loss of *Arf* or *p53* completely rescues the cell cycle re-entry defect of the *E2f3*^{-/-} MEFs, it only partially suppresses their asynchronous proliferation defect (A. Aslanian and J.A. Lees, unpubl.). Second, loss of *Arf* or *p53* has no detectable effect on the developmental phenotypes and the resulting embryonic/neonatal lethality of the *E2f3*^{-/-} mice (A. Aslanian and J.A. Lees, unpubl.). Thus, *E2f3* has at least one essential function that is *Arf/p53* independent. This second function remains to be established. We had previously concluded that the cell cycle re-entry defect of the *E2f3*^{-/-} MEFs reflected a direct role for *E2f3* in the activation of classic E2F-responsive genes. However, this current study shows that the defect in gene activation in the *E2f3*^{-/-} MEFs is fully reversed by the loss of *Arf* or *p53*. On the basis of the same logic outlined above, these results can be explained in two ways. First, the defect in activation of classic E2F-responsive genes in the *E2f3*^{-/-} cells could be an indirect consequence of activation of the p19^{Arf}-p53 pathway. Alternatively, *E2f3* may be required for the appropriate activation of classic E2F-responsive genes, but the consequent loss of this activation in E2F3-deficient cells is outweighed or overridden by the increased induction of these targets that results from the loss of *Arf* or *p53*. Given the extensive cross-talk between the pRB and p53 pathways, both models are highly plausible. More subtle experiments will be required to distinguish between these two possibilities.

Our analysis of the *E2f3* mutant cells reinforces a growing body of evidence that the p19^{Arf}-p53 network is the key determinant of the proliferation status of cultured primary fibroblasts (Sherr 2001). Several other transcriptional regulators, such as Bmi1, TBX2, TBX3, and Twist, have been linked to the repression of *Arf* and the inhibition of p53 signaling (Jacobs et al. 1999, 2000; Maestro et al. 1999; Brummelkamp et al. 2002; Lingbeek et al. 2002). There is limited insight into the mechanism(s) of action of these repressors. In vitro promoter mapping studies show that TBX2 and TBX3 can bind to a variant T-site located within the Initiator sequence of the human *Arf* promoter (Lingbeek et al. 2002). However, promoter binding has not been demonstrated in vivo. Similarly, antibodies against Bmi1 have not worked in ChIP assays. This is thought to be an issue of antibody accessibility, as Bmi1 is a component of the multiprotein polycomb complex (van Lohuizen 1998). However, it is unclear how the Bmi1-polycomb complex is recruited to

Arf, with respect to either the target DNA sequence/chromatin structure or the identity of the component(s) that mediate the DNA/chromatin binding. Our identification of E2F3 as an additional repressor of *Arf* raises additional questions. First, what is the precise nature of the repressive E2F3 complex? Is it a unique function of E2F3b or does E2F3a contribute? Does it involve a higher order, antibody-inaccessible pRB complex, or does it function in a pocket protein-independent manner? Second, what directs E2F3, but not other E2F complexes, to bind specifically to the *Arf* promoter in normal cells? Finally, what is the relationship between E2F3 and the other known *Arf* repressors? Do they function independently of one another or work cooperatively to ensure the repression of *Arf*? Careful analysis of both the repressor complexes and the *Arf* promoter will be required to unravel this complexity.

Our data show that E2F is also involved in the activation of *Arf* in response to oncogenic signals. Although there is extensive literature suggesting a link between E2F and *Arf* (Trimarchi and Lees 2002), this is the first study to demonstrate that the action of these proteins is direct. During oncogenic activation, we see recruitment of the endogenous E2F1 and, to a lesser extent, the other activating E2Fs, E2F2 (P. Iaquinta and J.A. Lees, unpubl.), and E2F3a. It is important to note that we do not completely lose the anti-E2F3a+b signal at the *Arf* promoter under conditions of oncogenic stress (Fig. 4B). We believe that this partially reflects differences in the level of oncogenic activation within the population of infected cells; some have sufficient E2F activation to disrupt the E2F3b repression, whereas others do not. The continued presence of p130 at the *p107* promoter in E1A-infected cells, strongly suggests that some cells express insufficient E1A to fully dissociate the pocket protein/E2F complexes. A second possibility is that the sustained anti-E2F3a+b signal at the induced *Arf* promoter reflects recruitment of transcriptionally active E2F3a. We suspect that this is the case, at least in the E1A-expressing cells, because we see a weak signal with the E2F3a-specific antibody and an enhanced signal with the anti-E2F3a+b antibody. Finally, as there are at least two E2F consensus-binding sites in the *Arf* promoter, we cannot rule out the possibility that E2F3b remains bound to the *Arf* promoter during the stress response, despite recruitment of E2F1 or other activating E2Fs. In this scenario, the activating E2Fs must somehow override or negate the repressive function of E2F3b to ensure *Arf* induction.

Importantly, this study provides considerable insight into the cross-talk between the two key tumor-suppressor networks, pRB-E2F and p19^{Arf}-p53. It is already well established that p53's growth-suppressive properties are at least partially dependent upon the ability of its downstream target, p21^{Cip1}, to inhibit phosphorylation of pRB and thereby promote its ability to repress E2F (Sherr 2001). In this study, we now show that E2F also plays a direct role in regulation of the p19^{Arf}-p53 pathway. Consistent with previous hypotheses, the activating E2Fs directly contribute to the induction of *Arf* that occurs in response to oncogenic stress, frequently referred to as the

tumor-surveillance response. In addition, our data show that E2F3 plays a key role in maintaining the p19^{Arf}-p53 network in the repressed state, when there is no oncogenic stress signal. There has been considerable debate as to how a cell could know whether it initiates inappropriate, as opposed to appropriate, proliferation, and regulate *Arf* accordingly (Lowe and Sherr 2003). It is well known that the state of E2F complexes is a key determinant of whether normal cells will divide. Our current finding that various E2F complexes contribute to both the repressed and activated states of *Arf* regulation strongly suggests that monitoring of E2F levels and/or activity is likely to lie at the heart of this tumor-surveillance mechanism.

Materials and methods

Generation of mouse strains and MEF preparation

E2f3^{+/-}; *Arf*^{+/-} and *E2f3*^{+/-}; *p53*^{+/-} mice were generated by intercrossing *E2f3*^{+/-} mice (Humbert et al. 2000) with either *Arf*^{+/-} mice (Kamijo et al. 1997) or *p53*^{+/-} (Williams et al. 1994), respectively. Genotyping was performed as previously described. Double heterozygous mutant mice were intercrossed, and MEFs were prepared from e13.5 embryos as previously described (Humbert et al. 2000). *Ink4a/Arf*^{+/-} mice (Serrano et al. 1996) were used to generate *Ink4a/Arf*^{+/-} MEFs.

Serum starvation and release experiments

Passage 4 MEFs were plated in triplicate onto 3.5-cm dishes at 2×10^5 cells/dish and cell cycle re-entry was performed as previously described (Humbert et al. 2000). After 48 h, cells were washed twice with DME and then incubated in low serum (0.1% FCS) for 72 h. Cells were subsequently fed with medium containing 10% FCS. For each timepoint, cells were labeled with 5 μ Ci of [³H]thymidine for 1 h. Cells were harvested and [³H]thymidine incorporation was measured as previously described (Moberg et al. 1996).

RNA preparation and Quantitative Real-time PCR analysis

Passage 4 MEFs were plated onto 15-cm dishes at 3×10^6 cells/dish and cell cycle re-entry was performed as described above. For each time point, cells were harvested and total RNA was isolated using RNeasy (Qiagen), and an on-column DNase step was performed according to the manufacturer's instructions. cDNAs were generated with Superscript First Strand Synthesis System (Invitrogen). Quantitative realtime PCR reactions using SYBR Green dye (Applied Biosystems) were run in triplicate on an ABI Prism 7000 Real-time PCR machine (Applied Biosystems). Control 18S rRNA reactions (Applied Biosystems) were also run to normalize Δ Ct values. Fold change was calculated as $2^{\Delta\Delta Ct}$. Primer sequences for *Arf* were 5'-CACCGGAATCCTGGACCAG-3' and 5'-GCAGTTCGAATCTGCACCGT-3', and for p107 were 5'-GATGCTCATCTGACCGGAGT-3' and 5'-ATAAGTCACGTAGCGCACA-3'.

Protein preparation, Western blotting, and gel-retardation assays

Passage 4 MEFs were plated onto 15-cm dishes at 3×10^6 cells/dish and cell cycle re-entry was performed as described above.

For each time point, cells were harvested and total protein was isolated as described previously (Moberg et al. 1996). Western blotting was performed with 100 μ g of whole-cell extract using anti-cyclin A (Santa Cruz sc-596), anti-p107 (Santa Cruz sc318), anti-p19^{Arf} (Novus NB200-106), anti-p16^{Ink4a} (Santa Cruz sc-1207), and anti-p21^{Cip1} (Santa Cruz sc-6246). In Figure 3D, extracts were prepared as above from asynchronous MEFs, or MEFs incubated in 0.1% serum for 3 d. Western blotting was performed on 30 μ g of extract using the anti-E2F3a+b antibody (sc-878, Santa Cruz). p53 gel-retardation assays were performed in the presence of supershifting antibody using NuShift (Geneka) according to the manufacturer's instructions.

Retroviral infection

Infections were performed exactly as described (Serrano et al. 1997), except that 15-cm plates were used at all steps, and the procedure was scaled up accordingly. Target *Ink4a/Arf*^{+/-} MEFs were selected for 2 d in 2 mg/mL puromycin, grown for a further 2 d, and then subjected to ChIP analysis as described below. pBabe-Puro, pBabe-Puro-E2F1 (Humbert et al. 2000), and LPC-12S-E1A have been described (de Stanchina et al. 1998).

ChIP

ChIP was performed essentially as described (Takahashi et al. 2000). Early-passage (passage 3–5) MEFs were used for all experiments. Sonicated, cross-linked chromatin corresponding to $\sim 3 \times 10^6$ cells was immunoprecipitated with the following antibodies: E2F1, sc-193; E2F3a, sc-879x; E2F3a+b, sc-878x; E2F4, sc-1082x; p130, sc-317x (all from Santa Cruz); pRB, MS-594 and MS-595 (Neomarkers); control (anti-Luciferase) 05-603 (Upstate Biotechnology). A total of 3%–4% of the precipitated DNA, or 0.5% input DNA, was amplified by 30 cycles of PCR using the following primer sequences: *p107* (5'-TTAGAGTCCGAGGTCATCTTCT-3' and 5'-GGGCTCGTCTCCGAACATATCC-3'), *Arf* (5'-GCTGGCTGTCACCGCGAT-3' and 5'-GCGTTGAGGCACCTCGAGA-3'), and *E2f1*-upstream (control, 5'-TGGAGGTCAAGTAGTGGCCCAA-3' and 5'-ACAATGTCTGGTTTGCTCCGCC-3'). PCR products were resolved on 8% polyacrylamide gels and stained with ethidium bromide.

Acknowledgments

We thank Chuck Sherr, Tyler Jacks, and Ron DePinho for providing *Arf*, *p53*, and *Ink4a/Arf* mutant mice, and also for stimulating discussions of this project. We are also grateful to Phil Sharp, Steve Bell, and members of the Lees lab for helpful discussions during this study and the preparation of this manuscript. J.A.L. is a Daniel K. Ludwig Scholar. This work was supported by a grant from the NIH (PO1-CA42063) to J.A.L.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Bates, S., Phillips, A.C., Clark, P.A., Stott, F., Peters, G., Ludwig, R.L., and Vousden, K.H. 1998. p14ARF links the tumour suppressors RB and p53. *Nature* **395**: 124–125.
- Bardino, T.A., Maclean, K.H., Brennan, J., Parganas, E., Yang, C., Aslanian, A., Lees, J.A., Sherr, C.J., Roussel, M.F., and Cleveland, J.L. 2003. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1

- loss. *Mol. Cell* **11**: 905–914.
- Ben-Israel, H. and Kleinberger, T. 2002. Adenovirus and cell cycle control. *Front. Biosci.* **7**: d1369–d1395.
- Berkovich, E., Lamed, Y., and Ginsberg, D. 2003. E2F and Ras synergize in transcriptionally activating p14ARF expression. *Cell Cycle* **2**: 127–133.
- Brummelkamp, T.R., Kortlever, R.M., Lingbeek, M., Trettel, F., MacDonald, M.E., van Lohuizen, M., and Bernards, R. 2002. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. *J. Biol. Chem.* **277**: 6567–6572.
- Chin, L., Pomerantz, J., and DePinho, R.A. 1998. The INK4a/ARF tumor suppressor: One gene—two products—two pathways. *Trends Biochem. Sci.* **23**: 291–296.
- de Stanchina, E., McCurrach, M.E., Zindy, F., Shieh, S.Y., Ferbeyre, G., Samuelson, A.V., Prives, C., Roussel, M.F., Sherr, C.J., and Lowe, S.W. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. *Genes & Dev.* **12**: 2434–2442.
- DeGregori, J., Leone, G., Miron, A., Jakoi, L., and Nevins, J.R. 1997. Distinct roles for E2F proteins in cell growth control and apoptosis. *Proc. Natl. Acad. Sci.* **94**: 7245–7250.
- Dimri, G.P., Itahana, K., Acosta, M., and Campisi, J. 2000. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. *Mol. Cell. Biol.* **20**: 273–285.
- Hanahan, D. and Weinberg, R.A. 2000. The hallmarks of cancer. *Cell* **100**: 57–70.
- He, Y., Armanious, M.K., Thomas, M.J., and Cress, W.D. 2000. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. *Oncogene* **19**: 3422–3433.
- Honda, R. and Yasuda, H. 1999. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. *EMBO J.* **18**: 22–27.
- Humbert, P.O., Verona, R., Trimarchi, J.M., Rogers, C., Dandapani, S., and Lees, J.A. 2000. E2f3 is critical for normal cellular proliferation. *Genes & Dev.* **14**: 690–703.
- Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999. The oncogene and Polycomb-group gene *bmi-1* regulates cell proliferation and senescence through the *ink4a* locus. *Nature* **397**: 164–168.
- Jacobs, J.J., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P.M., van Welsem, T., van de Vijver, M.J., Koh, E.Y., Daley, G.Q., et al. 2000. Senescence bypass screen identifies TBX2, which represses *Cdkn2a* (p19(ARF)) and is amplified in a subset of human breast cancers. *Nat. Genet.* **26**: 291–299.
- Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell* **91**: 649–659.
- Leone, G., Nuckolls, F., Ishida, S., Adams, M., Sears, R., Jakoi, L., Miron, A., and Nevins, J.R. 2000. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. *Mol. Cell. Biol.* **20**: 3626–3632.
- Lingbeek, M.E., Jacobs, J.J., and van Lohuizen, M. 2002. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. *J. Biol. Chem.* **277**: 26120–26127.
- Llanos, S., Clark, P.A., Rowe, J., and Peters, G. 2001. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. *Nat. Cell Biol.* **3**: 445–452.
- Lowe, S.W. and Sherr, C.J. 2003. Tumor suppression by Ink4a-Arf: Progress and puzzles. *Curr. Opin. Genet. Dev.* **13**: 77–83.
- Maestro, R., Dei Tos, A.P., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D.H., and Hannon, G.J. 1999. Twist is a potential oncogene that inhibits apoptosis. *Genes & Dev.* **13**: 2207–2217.
- McCaffrey, J., Yamasaki, L., Dyson, N.J., Harlow, E., and Griep, A.E. 1999. Disruption of retinoblastoma protein family function by human papillomavirus type 16 E7 oncoprotein inhibits lens development in part through E2F-1. *Mol. Cell. Biol.* **19**: 6458–6468.
- Moberg, K., Starz, M.A., and Lees, J.A. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. *Mol. Cell. Biol.* **16**: 1436–1449.
- Palmero, I., Pantoja, C., and Serrano, M. 1998. p19ARF links the tumour suppressor p53 to Ras. *Nature* **395**: 125–126.
- Palmero, I., Murga, M., Zubiaga, A., and Serrano, M. 2002. Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2. *Oncogene* **21**: 2939–2947.
- Pan, H., Yin, C., Dyson, N.J., Harlow, E., Yamasaki, L., and Van Dyke, T. 1998. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. *Mol. Cell* **2**: 283–292.
- Parisi, T., Pollice, A., Di Cristofano, A., Calabro, V., and La Mantia, G. 2002. Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. *Biochem. Biophys. Res. Commun.* **291**: 1138–1145.
- Phillips, A.C. and Vousden, K.H. 2001. E2F-1 induced apoptosis. *Apoptosis* **6**: 173–182.
- Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* **92**: 713–723.
- Radfar, A., Unnikrishnan, I., Lee, H.W., DePinho, R.A., and Rosenberg, N. 1998. p19(ARF) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. *Proc. Natl. Acad. Sci.* **95**: 13194–13199.
- Rowland, B.D., Denisov, S.G., Douma, S., Stunnenberg, H.G., Bernards, R., and Peeper, D.S. 2002. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. *Cancer Cell* **2**: 55–65.
- Russell, J.L., Powers, J.T., Rounbehler, R.J., Rogers, P.M., Conti, C.J., and Johnson, D.G. 2002. ARF differentially modulates apoptosis induced by E2F1 and Myc. *Mol. Cell. Biol.* **22**: 1360–1368.
- Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. 1996. Role of the INK4a locus in tumor suppression and cell mortality. *Cell* **85**: 27–37.
- Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **88**: 593–602.
- Sherr, C.J. 1996. Cancer cell cycles. *Science* **274**: 1672–1677.
- . 2001. The INK4a/ARF network in tumour suppression. *Nat. Rev. Mol. Cell. Biol.* **2**: 731–737.
- Sherr, C.J. and DePinho, R.A. 2000. Cellular senescence: Mitotic clock or culture shock? *Cell* **102**: 407–410.
- Sherr, C.J. and Roberts, J.M. 1999. CDK inhibitors: Positive and negative regulators of G₁-phase progression. *Genes & Dev.* **13**: 1501–1512.
- Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K.H., et al. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. *EMBO J.* **17**: 5001–5014.
- Takahashi, Y., Rayman, J.B., and Dynlacht, B.D. 2000. Analysis

Aslanian et al.

- of promoter binding by the E2F and pRB families in vivo: Distinct E2F proteins mediate activation and repression. *Genes & Dev.* **14**: 804–816.
- Tolbert, D., Lu, X., Yin, C., Tantama, M., and Van Dyke, T. 2002. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. *Mol. Cell. Biol.* **22**: 370–377.
- Trimarchi, J.M. and Lees, J.A. 2002. Sibling rivalry in the E2F family. *Nat. Rev. Mol. Cell. Biol.* **3**: 11–20.
- Tsai, K.Y., Hu, Y., Macleod, K.F., Crowley, D., Yamasaki, L., and Jacks, T. 1998. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. *Mol. Cell* **2**: 293–304.
- Tsai, K.Y., MacPherson, D., Robinson, D.A., Crowley, D., and Jacks, T. 2002. ARF is not required for apoptosis in Rb mutant mouse embryos. *Curr. Biol.* **12**: 159–163.
- van Lohuizen, M. 1998. Functional analysis of mouse Polycomb group genes. *Cell. Mol. Life Sci.* **54**: 71–79.
- Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J., and Bar-Sagi, D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. *Nat. Cell Biol.* **1**: 20–26.
- Williams, B.O., Remington, L., Albert, D.M., Mukai, S., Bronson, R.T., and Jacks, T. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. *Nat. Genet.* **7**: 480–484.
- Yamasaki, L., Bronson, R., Williams, B.O., Dyson, N.J., Harlow, E., and Jacks, T. 1998. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. *Nat. Genet.* **18**: 360–364.
- Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* **92**: 725–734.
- Ziebold, U., Reza, T., Caron, A., and Lees, J.A. 2001. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. *Genes & Dev.* **15**: 386–391.
- Ziebold, U., Lee, E.Y., Bronson, R.T., and Lees, J.A. 2003. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. *Mol. Cell. Biol.* **23**: 6542–6552.
- Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J., and Roussel, M.F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes & Dev.* **12**: 2424–2433.
- Zindy, F., Williams, R.T., Baudino, T.A., Reh, J.E., Skapek, S.X., Cleveland, J.L., Roussel, M.F., and Sherr, C.J. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. *Proc. Natl. Acad. Sci.* **100**: 15930–15935.

Repression of the *Arf* tumor suppressor by E2F3 is required for normal cell cycle kinetics

Aaron Aslanian, Phillip J. Iaquinta, Raluca Verona, et al.

Genes Dev. 2004, **18**:

Access the most recent version at doi:[10.1101/gad.1196704](https://doi.org/10.1101/gad.1196704)

References

This article cites 53 articles, 22 of which can be accessed free at:
<http://genesdev.cshlp.org/content/18/12/1413.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).